

**Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.**

Substitute for form 1449PTO				Complete If Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				Application Number	10/776,180
				Filing Date	02/12/2004
				First Named Inventor	Marc Beauregard
				Art Unit	
				Examiner Name	
Sheet	1	of	3	Attorney Docket Number	15493-2US MG/al




## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1

## FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	12/07/05
--------------------	---	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.<sup>1</sup> Applicant's unique citation designation number (optional).<sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04.<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.<sup>6</sup> Applicant is to place a check mark here if English language Translation is

place a check mark here if English language Translation is  
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file  
(and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2  
hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the  
individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to  
the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR  
COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450

**COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**  
**DOCSOLEIL: If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449PTO				Complete If Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				Application Number	10/776,180
Sheet	2	of	3	Filing Date	02/12/2004
				First Named Inventor	Marc Beauregard
				Art Unit	
				Examiner Name	
				Attorney Docket Number	15493-2US MG/al


NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
B1	Stemmer, (1994), Proc. Natl. Acad. Sci. USA, <u>91</u> :10747-10751		
B2	Cox, (1976), Annu. Rev. Genet. <u>10</u> :135-156		
B3	Shortle, (1983), Methods Enzymol., <u>100</u> :457-468		
B4	Mott et al., (1984) Nucleic Acids Res., <u>12</u> :4139-4152		
B5	Chiang L. et al., (1993), PCR Methods Appl., <u>2</u> :210-217		
B6	Leung, D.W. et al., (1989) Technique, <u>1</u> :11-15		
B7	Chao K.M. (1992), Comput. Appl. Biosci., <u>8</u> :481-487		
B8	Cadwell and Joyce, (1992) PCR methods appl. <u>2</u> :28-33		
B9	Vartanian et al., (1996), Nucleic Acids Res., <u>14</u> :2627-2631		
B10	New England Biolabs Inc (2002-2003)		

Examiner Signature		Date Considered	12/10/2003
--------------------	---	-----------------	------------

\*EXAMINER if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

DOCSQUE:  If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/776,180
(use as many sheets as necessary)				Filing Date	02/12/2004
Sheet	3	of	3	First Named Inventor	Marc Beauregard
				Art Unit	
				Examiner Name	
				Attorney Docket Number	15493-2US MG/al

B11	Grundy et al., Crystallization and Stabilization of MB-1, a de novo designed protein for optimized feeding technology, Journal of Biotechnology 63 (1998) 9-15.	
B12	Fromant et al., Direct Random Mutagenesis of Gene-Sized DNA Fragments Using Polymerase Chain Reaction, Analytical Biochemistry 224, 347-353 (1995).	

Examiner Signature		Date Considered	12/17/08
--------------------	---	-----------------	----------

\*EXAMINER if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

DOCSQUE:  If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.